Cytosorbents Corp. 10-Q Summary: Quarter Ended March 31, 2011
Business Context and Reporting Period
Cytosorbents Corp. is a development-stage company focused on the research, development, and commercialization of the CytoSorbTM device, a blood purification technology designed to remove toxins and cytokines from blood. The company reported for the quarterly period ended March 31, 2011. As of this date, the company had not generated any revenue and remains dependent on financing to fund operations. In March 2011, the company received CE Mark approval for the CytoSorb device in the European Union.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,214,584) | $(969,051) |
| Net Loss Available to Common Shareholders | $(1,956,229) | $(1,750,415) |
| Operating Expenses | $1,128,491 | $967,777 |
| Cash and Cash Equivalents (Ending) | $2,436,465 | $1,346,301 |
| Net Cash Used in Operating Activities | $(587,954) | $(421,827) |
| Net Cash Provided by Financing Activities | $1,968,750 | $172,500 |
| Total Liabilities | $1,723,895 | N/A |
| Accumulated Deficit (Inception to Date) | $(85,945,079) | N/A |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased by approximately $1.38 million from the beginning of the period ($1,055,669) to the end ($2,436,465), driven primarily by financing activities.
- Financing Activity: The company raised $1,250,000 in proceeds from the issuance of convertible notes and $718,750 in equity contributions. Additionally, $691,840 of convertible notes were converted into common stock.
- Expense Growth: Total operating expenses increased by approximately 16.6% compared to the same period in 2010, with Research and Development expenses rising from $681,215 to $759,157.
- Debt Structure: Convertible notes payable (net of discount) decreased from $1,077,388 to $493,844 due to conversions to equity and amortization of debt discounts.
Outlook, Risks, and Management Commentary
- Commercialization Status: The company received CE Mark approval in March 2011, allowing sales in the European Union. Management plans to begin commercialization in Europe and is preparing for a controlled-market release.
- Clinical Progress: The European Sepsis clinical trial has enrolled 100 patients across 14 hospital units. Results demonstrated the device's ability to reduce circulating cytokine levels with no serious device-related adverse events reported in over 300 treatments.
- Liquidity Outlook: Management believes current cash reserves are sufficient to fund operations into the first quarter of 2012. Additional funding will be required thereafter to complete clinical studies and commercialize products.
- Funding Mechanism: The company has an effective registration statement for a purchase agreement with Lincoln Park Capital Fund, LLC, allowing for the sale of up to $6 million of common stock over 750 days.
- Risks: The filing includes a "Going Concern" warning, noting substantial doubt about the company's ability to continue as a going concern without additional financing. There is no assurance of FDA approval for the U.S. market or successful commercialization.
Investor Verification Checklist
- Runway Validation: Verify if the $2.4 million cash balance is sufficient to reach the projected Q1 2012 funding milestone given current burn rates.
- Financing Terms: Review the specific terms of the Lincoln Park Capital Fund agreement and the recent convertible notes (8% interest, $0.10 conversion price) to assess potential dilution.
- Regulatory Path: Confirm the timeline and requirements for FDA 510(k) or PMA approval in the United States, as CE Mark approval does not guarantee U.S. market access.
- Preferred Stock Obligations: Assess the impact of outstanding Series A and Series B preferred stock dividends and conversion rights on common shareholders.
- Patent Portfolio: Verify the status of the 29 issued patents and pending applications to ensure intellectual property protection remains intact.